Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Sells $282,299.76 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 492 shares of Intuitive Surgical stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $573.78, for a total value of $282,299.76. Following the completion of the transaction, the senior vice president now directly owns 4,056 shares in the company, valued at $2,327,251.68. This represents a 10.82 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $568.02 on Thursday. The firm has a market cap of $202.32 billion, a P/E ratio of 88.61, a P/E/G ratio of 5.85 and a beta of 1.43. The business’s fifty day moving average is $571.70 and its two-hundred day moving average is $530.90. Intuitive Surgical, Inc. has a 52 week low of $364.17 and a 52 week high of $616.00.

Hedge Funds Weigh In On Intuitive Surgical

A number of institutional investors and hedge funds have recently bought and sold shares of ISRG. Atala Financial Inc acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at $25,000. Berbice Capital Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at $26,000. Parvin Asset Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at $26,000. BankPlus Trust Department acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at $28,000. Finally, Hurley Capital LLC acquired a new position in Intuitive Surgical in the fourth quarter valued at about $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Barclays lifted their target price on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Raymond James lifted their price target on Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a report on Friday, January 24th. Evercore ISI boosted their target price on Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. UBS Group lifted their price target on Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Finally, Wells Fargo & Company lifted their price target on Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.